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MaCell death is desirable in cancer cells and undesirable in organs with limited regenerative potential, like the heart. Cell death
comes inmany forms, but only apoptosis and toa lesserdegreenecrosis is currently relevant to the clinical imager.Noninvasive
imaging of cell death is an attractive option to understand pathophysiology, track disease activity, and evaluate response to
intervention. Apoptosis seems to be themost promising target for imaging cell death, because it could be reversible andmight
be modulated with interventions. Molecular, nuclear, optical, or magnetic resonance imaging–based methods have been
developed to identify intermediate steps in the apoptosis cascade. Animal studies show promising results for noninvasive
imaging in various cardiovascular diseases. Human studies have shown feasibility, but clinical use is yet inconclusive.
Newer technologies offer promise, especially for tracking apoptosis in evaluation of novel therapeutic interventions.
(J AmColl Cardiol Img2018;11:476–93)©2018PublishedbyElsevier on behalf of the American College of Cardiology Foundation.C ell death is an important feature of both lifeand death (1). It is intricately controlled inembryonic development as well as in post-
natal life, when pathways are turned on and off as
needed in exquisitely choreographed patterns, as
best seen in apoptotic cell death. The machinery for
controlled cell death, especially via apoptosis, per-
sists into adult life to get rid of unwanted cells
including cancerous and senescent ones, controlling
the immune response as well as providing immune
privilege in organs where cell death–mediated inﬂam-
mation can be harmful. However, these same tightly
regulated pathways can get activated in many
diseases and once out of the carefully controlled
environment, can have fateful consequences. Cell
death is undesirable in heart diseases, which has
limited regenerative capacity but may be desired forN 1936-878X/$36.00
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strong evidence that cell death, especially of the
apoptotic variety, can be modulated. In either case,
detection, monitoring of cell death, and assessment
of therapeutic response might need accurate
measurement of apoptosis (2,3). Visualizing cell
death, especially through noninvasive imaging, is
thus critical for understanding disease, tracking its
course, prognostication, and even directing targeted
therapy as well as measuring the success of such
treatments.
HOW SHOULD AN IMAGER THINK ABOUT
CELL DEATH?
At least 12 forms of cell death have been described so
far (4), and more are being reported; however, onlyhttps://doi.org/10.1016/j.jcmg.2017.11.018
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AB BR E V I A T I O N S
AND ACRONYM S
GSAO = 4-(N-[S-
glutathionylacetyl]amino)
phenylarsonous acid
PE =
phosphatidylethanolamine
PET = positron emission
tomography
PS = phosphatidylserine
SPECT = single-photon
emission computed
tomography
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 1 , N O . 3 , 2 0 1 8 Shekhar et al.
M A R C H 2 0 1 8 : 4 7 6 – 9 3 Targeted Imaging for Cell Death
477apoptosis, and to a lesser degree necrosis and auto-
phagy, could be seen as a current priority for the
imager (Central Illustration). All forms of cell death
follow a rather similar general pattern of onset and
progression—death programs are activated by a vari-
ety of factors including ischemia, cytokines, oxidative
stress, starvation, toxins, and infections. These trig-
gers either act at the cell surface, activating death-
associated receptors (extrinsic pathways), or, as in
radiation injury, act intracellularly (intrinsic path-
ways); often, both pathways are activated in an inter-
related manner to various degrees. Most pathways
converge to the mitochondria (5), and often it is the
degree of mitochondrial disruption that decides how
the cell dies.
Necrosis (Central Illustration), the most well-
established form of cell death, signiﬁes irreversible
damage to the mitochondria—opening of the mito-
chondrial permeability transition pore results in
collapse of its voltage gradient and thus energy
depletion (6). It is often acute and dramatic, provok-
ing strong inﬂammatory and immune responses in its
neighborhood through en mass release of cellular
contents. It is imaged to detect and quantitate dam-
age rather than with any hope of reversing it.
Apoptosis and autophagy are more nuanced, in that
death occurs in a controlled manner without pro-
voking an inﬂammatory response. Apoptosis (Central
Illustration) is a form of programmable cell death,
where a very speciﬁc death pathway made up of
sequential steps is activated to remove cells. Auto-
phagy is a form of lysosomal degradation of cell
contents within the degenerate or senescent cell it-
self, but there is controversy whether it is more of a
survival mechanism rather than committed cell
death. These forms of cell death show an insidious
cellular involution or digestion without macroscopi-
cally disrupting the cell membrane, and remnants are
engulfed by scavenger cells like macrophages; thus,
dying cell bodies disappear without much trace,
which makes imaging them more difﬁcult. However,
they can contribute to severe organ dysfunction,
especially when they occur in sufﬁcient magnitude
and over a signiﬁcant time period in organs with poor
regenerative capacity like the heart. More impor-
tantly, because apoptosis (and to a lesser extent
autophagy) can be modulated, imaging it might have
important implications for therapy and preserving
organ structure and function. Yet another type of cell
death, necroptosis (7), is gaining signiﬁcant interest
(Central Illustration, lower left panel); it is a condition
where the cellular morphology is consistent with
necrosis, but its execution appears to be programmed
like in apoptosis (7). Necroptosis-triggering stimulicreate a necrosome that induces membranous
leak, and similar to cellular necrosis, one
might be able to use intracellular targets for
noninvasive imaging.
It appears that many of these pathways
share elements and can inﬂuence each other
(8,9). Damaged mitochondria are potent
triggers of apoptosis, and removing them
via autophagy can attenuate apoptosis.
Similarly, apoptosis and necroptosis share a
seesaw relationship, where caspases mediate
apoptosis, but inefﬁcient caspase 8 activation
shifts the pathway to death via necroptosis.
In each of these processes, depending on the energetic
state, the cell may complete apoptosis if adenosine
triphosphate (ATP) levels are adequate for preserving
pumps, may enter a zombie state (where the cell
survives by turning down most energy-intensive pro-
cesses, like contraction, and concentrates on barely
staying alive) if ATP is marginal, and ends in necrosis if
ATP levels are depleted so much that they cannot
sustain the membrane pumps. The Central Illustration
shows various targets that are amenable to imaging in
each of the major forms of cell death.
MOLECULAR IMAGING TECHNIQUES,
AGENTS, AND TARGETS FOR IMAGING
NECROTIC CELLS
Interest in imaging necrosis peaked 2 decades ago,
and innovation has now shifted toward apoptosis
imaging; necrotic imaging will thus be considered
only brieﬂy in this review. The waning interest in
molecular imaging of necrosis is understandable,
because unlike apoptosis, it is a late stage of cell
injury that limits options for intervention. Moreover,
necrosis is, under many circumstances, rather an
extension of apoptotic injury, and interference in the
apoptotic process could restrict necrotic cell loss (9).
A critical difference between imaging apoptosis
and necrosis is that the latter allows for targeting
intracellular constituents secondary to disrupted cell
membranes that are no longer a barrier to penetration
of imaging agents. However, this condition also cre-
ates difﬁculties in imaging, because many intracel-
lular targets could wash out (e.g., histones) or offer
shorter time windows for imaging, and might need at
least some residual perfusion to carry the tracer to the
desirable target. Finally, imaging should be able to
differentiate acute from subacute necrosis and ne-
crosis from apoptosis when both coexist, as they
frequently do.
Two different strategies have been used to detect
cell necrosis. Static imaging techniques detect
CENTRAL ILLUSTRATION Pathways of Apoptotic, Necroptotic, and Necrotic Cell Death
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479morphological changes (structure, function, and
chemistry) and thus image the effect of damage due
to cell death. Other techniques allow real-time im-
aging of cell death itself, using radionuclide tracers
that penetrate and target intracellular markers to
localize cells undergoing necrosis. The former in-
cludes echocardiography, cardiac magnetic resonance
(CMR), and computed tomography (CT). CMR can
detect acute myocardial infarction (MI), often within
20 to 30 min of onset through detection of edema and
subsequently through detection of replacement
ﬁbrosis by late gadolinium enhancement (LGE). T2
mapping can detect edema but is not speciﬁc for the
necrotic tissue and cannot differentiate acute from
subacute myocardial injury. In addition, these detect
residual effects of myocardial necrosis rather than the
process, and hence, are least useful in ﬁnding an
indication for acute therapeutic intervention targeted
to modulate cell death.
The other strategy is to bind intracellular contents
exposed by necrotic cell membranes. Early studies of
vital ﬂuorochromes such as propidium iodide exploi-
ted this access to intracellular contents, and other
agents, such as indium-111-labeled antimyosin anti-
bodies (10), technetium-99m (99mTc)–pyrophosphate
(11), and 99mTc-labeled D-glucaric acid (12), later
reﬁned this further. Antimyosin antibody imaging has
the most data and has been used to detect necrosis in a
number of pathologies including MI, myocarditis,
cardiomyopathy, and transplant rejection (13).
More recently, 4-(N-[S-glutathionylacetyl]amino)CENTRAL ILLUSTRATION Continued
(A) APOPTOSIS. There are 2 basic pathways to mediate apoptosis—the int
where intracellular triggers like cellular stress lead to mitochondrial pe
cytochrome C, and formation of the apoptosome (a combination of APA
caspases (3 and 7), resulting in deoxyribonucleic acid (DNA) fragmentat
pathway for apoptosis. Engagement of the death receptors (with TNF alp
is disubiquitylated (uRIPK1), and mediates apoptosis via caspase 8 and th
in DNA fragmentation and apoptosis. In every process of apoptosis, depe
levels are adequate for preserving pumps, enter a zombie state if ATP is m
that they cannot sustain the membrane pumps. (Right) Possible imagin
intracellular. The former include exteriorized cell surface phospholipids
exteriorized histones, and the La antigen that translocates from the nu
stages of apoptosis). Nonexteriorized targets include probes for mitoch
gadolinium-based CMR probes can access DNA fragments in later stages
pathway uses the same pathways as apoptosis but with some differenc
ubiquitylated (uRIPK1) and there is caspase 8 inhibition, the cell gets d
instead. This is mediated via the RIPK3–MLKL complex and results in a
mitochondria with ATP depletion). Imaging targets for necroptosis inclu
membrane and mitochondria that resemble a mixture of apoptosis and
development. (Right) Should the damage be severe or should apoptosis
morphs into necrosis, a largely irreversible form of cell death. Because
imaging targets for necrosis include many of the intracellular componen
imaged with a number of nuclear and CMR techniques.phenylarsonous acid (GSAO), an arsenic compound
tagged with indium-111 (Figure 1) has been used to
home into dithiol-containing substrates in the cell to
identify cell death (14). It has an absolute requirement
for membrane disruption and has little persistence
in the extracellular space, which makes for better
images.
Magnetic resonance (MR) imaging allows for
sophisticated imaging of cell death, such as, with
gadoporphyrin (which accumulates in necrotic tis-
sue), using magnetic nanoparticles coupled to an
antibody (iron oxide–labeled antimyosin antibodies)
or gadolinium with diethylenetriaminepentacetate þ
annexin-V–cross-linked iron oxide can harness the
advantages of MR to image cellular necrosis, track the
time course of changes, and distinguish necrosis from
apoptosis when they occur together (15). Deoxy-
ribonucleic acid (DNA)–binding chelates are a marker
for necrosis (16), and newer DNA-binding gadolinium
chelates (such as Gd-TO) have been developed (17)
that speciﬁcally bind to exposed DNA in acutely
necrotic cells, but do not wash away like standard
gadolinium and allow for studying the time course of
acute necrosis (Figure 2). As small molecules, they
might avoid issues like renal and hepatic retention
that are seen with large molecules, like antibodies.
Further, hyperpolarized 13C-carbon MR imaging,
where polarization of the magnetic spins is used to
increase magnetization and thus, the signal, many
fold during spectroscopy or MR-based imaging, is
being used to detect and localize in necrotic tissues. Itrinsic pathway or the extrinsic pathway. (Left) The intrinsic pathway,
rmeability transition pore formation, collapsing voltage, leak of
F1, Caspase 9, and cytochrome C). This can activate the executioner
ion and the classic apoptotic morphology. (Middle) The extrinsic
ha, FAS, or other ligands) results in TRAD-RIPK1 activation if RIPK1
en by activating the executioner caspases 3 and 7. This again results
nding on the energetic state, the cell may complete apoptosis if ATP
arginal, and end in necrosis if ATP levels are depleted so much that
g targets for apoptosis can be exposed to the cell surface or
like phosphatidylethanolamine (PE) and phosphatidylserine (PS),
cleus to the cytoplasm (which can be accessed for imaging in later
ondrial voltage and its integrity, and caspase activation. Some
of apoptosis. (B) Necroptosis and necrosis. (Left) The necroptosis
es—should TRAD-RIPK1 activation occur when RIPK1 is dis-
iverted from an apoptotic fate and enters the necroptosis pathway
necrotic morphology (membrane permeabilization and swelling of
de Nec-I–based probes and ﬁnding morphological changes in the
necrosis. However, NEC-1 imaging is in a very early stage of
or necroptosis present with severe energy depletion, the process
necrosis is associated with signiﬁcantly compromised membranes,
ts—myosin, dithiols like HSP90, Filamin A, and so on. They can be
FIGURE 1 Finding Newer Targets for Imaging Cell Death
In vivo imaging
Transverse Coronal Sagittal
Ex vivo imaging
Intact GSAO is membrane
impermeable
Legend
Membrane disruption in necrotic cells allows cell
entrance of fluorescently or radiolabeled GSAO
and binding to intracellular dithiol molecules
Membrane bound GGT (on proliferating
and stressed cells) splices off glutamyl
residue and allows cell entrance of
metabolite GCAO
GSAO
Glutamyl residue on GSAO
Dithiol molecules (target)
GGT, γ-glutamyl transferase
Nucleus
Fluorescent or radiolabel
GCAO
Binding of fluorescent or radioactive
reporter molecules to GSAO prevents
binding to GGT and thereby prevents
all access over intact membrane
A
B
As also presented in Figure 2, whereas duramycin is being developed as the new agent for
apoptosis imaging, 4-(N-[S-glutathionylacetyl]amino)phenylarsonous acid (GSAO) has
been reported as a new necrosis targeting agent. (A) Targeting mechanism of GSAO. GSAO
binds to dithiol molecules, which are abundant in the intracellular space and virtually
absent in the extracellular space. When labelled with radioactive or ﬂuorescent reporter
molecules, GSAO cannot negotiate across the cell membrane of healthy cells (top) but
gains free access through disrupted membranes of dying cells (bottom). Thus, GSAO
accumulates in dying cells. (B) In-111 GSAO imaging in rabbit ischemia-reperfusion model
with acute myocardial infarction. In vivo mSPECT (top), and fused mSPECT/mCT images
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480can study the biochemistry of necrosis in real time in
the living organ (18,19), detecting accumulation of
lactate (with reduced bicarbonate production sug-
gesting interruption of the Krebs cycle) or detecting
fumarase leakage with resulting malate production to
detect and localize in necrotic tissues during
ischemia-reperfusion (20). This method can detect
early damage compared with the information
obtained through scar imaging with CMR-LGE.
Molecular imaging is thus providing some
exciting avenues to image and protect against cell
death (21,22).
Necroptosis has been noted in ischemia-
reperfusion injury in multiple organs including the
heart, kidney, and brain. It is important in sepsis
(23), and has a particularly signiﬁcant role in cancer,
where cells try to evade apoptosis (24). Necroptosis
imaging is still in its infancy, and most of the
detection is in vitro. A small molecule necrostatin-1
(Nec-1) is a speciﬁc inhibitor of the main compo-
nent of the necrosome (RIP1–RIP3 interaction) and
has been tagged with a radionuclear tag for imaging
necroptosis; necroptosis is prominent in human
carotid plaque necrotic core and is thought to be
important for plaque vulnerability. Ex vivo imaging
shows 123I-Nec-1 localizes to the atherosclerotic pla-
ques with necroptotic cells in (human) high-risk
atherosclerotic plaques. Mice studies show the po-
wer of Nec-1 imaging, because inhibiting necroptosis
reduced atherosclerotic lesion size and other in-
dicators of plaque instability (25). No in vivo human
studies imaging necroptosis have been undertaken
yet.
MOLECULAR IMAGING TECHNIQUES,
AGENTS, AND TARGETS FOR
IMAGING AUTOPHAGY
Autophagy imaging is evolving but has remained far
behind apoptosis imaging—most of the studies are
limited to studying autophagy ﬂux or markers in tis-
sues or in biopsy samples. One reason is that, despite
being seen in myocardial ischemia, ischemia/reper-
fusion (IR) injury, and heart failure, its role is less
understood, and it is unclear whether increased(middle) revealed intense tracer uptake. There was only minimal
uptake of radiotracer control compound In-111 GSCA (not shown).
Ex vivo planar images conﬁrmed intense In-111 GSAO uptake
(bottom). g-counting of myocardial sections conﬁrmed that
In-111 GSAO uptake in infarct was higher than in the remote area
and higher than In-111 GSCA uptake in the infarct (not shown).
Panel A adapted from Tahara et al. (14).
FIGURE 1 Continued
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481autophagy mediates heart failure or if it is a periph-
eral phenomenon (26). A second more important
reason is a lack of robust probes coupled to currently
available tomographic imaging (27). A cathepsin-
activatable near-infrared ﬂuorochrome (CAF-680)
has been successfully used for studying the role of
modulating autophagy in mice IR injury and tracks
change in infarct size reasonably well (28). However,
ﬂuorescence molecular tomography use has limited
potential for clinical translation. No good studies
exist to show autophagy imaging in human health
and disease. Future development of traditional im-
aging probes (e.g., positron-emission tomography
[PET]–based) rather than the current ﬂuorescence-
based ones will be needed for human translation.
MOLECULAR IMAGING TECHNIQUES,
AGENTS, AND TARGETS FOR IMAGING
APOPTOTIC CELLS
Noninvasive imaging of cell death has been mostly
directed at apoptosis, given that such cells may still
be salvageable, compared with the irreversible dam-
age that necrosis often represents. Apoptosis imaging
has been used to understand pathophysiology, direct
therapy, and quantitate beneﬁt of therapy, more so in
published cancer data than in cardiovascular condi-
tions. A number of targets have been investigated for
noninvasive imaging of apoptotic cell death (Central
Illustration). These include cell surface markers,
detection of membrane permeability, activation of
intracellular apoptotic machinery (e.g., caspases),
and mitochondrial imaging.
SURFACE MARKERS—EXTERIORIZED PHOSPHOLIPIDS.
Nuclear techniques for apoptosis imaging. Phospholipids,
such as phosphatidylethanolamine (PE) and phos-
phatidylserine (PS), which are normally residents of
the interior layer of the sarcolemma, are exposed
during apoptosis and comprise attractive targets for
noninvasive imaging. PS and PE accumulate in a
time- and damage-dependent manner and result in a
concentration that constitutes an attractive target for
positively-charged probes, carrying either a diag-
nostic tracer or even a therapeutic tag. A number of
molecules have been deployed for detecting PS
exteriorization; the best known among them is
annexin-V complexed to a radionuclide technetium-
99m. It has been even used in early-stage clinical
studies (Figures 3 to 5).
Annexin-V, a positively-charged, naturally occur-
ring protease with anticoagulant activity, has nano-
molar afﬁnity to the negatively-charged PS on the cell
surface of apoptotic cells. Radiolabeling arecombinantly produced annexin-V with 99mTc gen-
erates an attractive probe to image apoptotic cells in
numerous cardiovascular disorders (29), including
atherosclerosis, MI, heart failure, and transplant
rejection, as also in various cancers before and after
therapy (30). It has also been safely tested in humans
with reasonable results (2,3,31). An iodinated probe,
123I-annexin-V, with a bit longer half-life is also being
tested, but data on cardiac apoptosis is lacking.
Because usual linker technology can target any of the
21 lysine NH2s, other site-speciﬁc modiﬁcations of
annexin-V, including 99mTc(CO)3-HIS-cys-annexin-V,
99mTc-annexin-V-117, 99mTc-His10-annexin-V, or
99mTc-Cys-annexin-V, or using 18F-labeled annexin-V
might improve efﬁcacy for imaging cell death. It has
also been postulated that PS imaging with annexin-V
can be used to detect ischemic memory after a brief
period of ischemia (32). Of note, annexin-V is not
speciﬁc for cardiomyocytes and is taken up by any
apoptotic cells, such as macrophages in atheroscle-
rotic necrotic cores (33,34).
Annexin-V’s adoption into clinical practice has
been slow due to some inherent disadvantages. As a
large molecule, it is cleared slowly and results in
signiﬁcant off-target radiation, especially to the kid-
ney (35). Most of the studies involving detection of
cell-surface PS have involved 99mTc-Annexin-V for
single-photon emission computed tomography
(SPECT) or SPECT/CT imaging (36,37), but PET
(38–40) or CMR (41–43) with superparamagnetically
labeled annexin-V, Gd liposomes with annexin-V
coating, and ligand-coated microbubbles (e.g. selec-
tin) have also been used.
A number of laboratories (44–47) including our
own have now championed the use of smaller probes
to target the other surface phospholipid molecule that
is exteriorized in apoptosis: PE. PE is more abun-
dantly expressed (20% to 25% of the inner-
phospholipid bilayer is PE compared with under
10% for PS) making it a higher signal target. It can be
detected with 99mTc-labeled duramycin, a small-
molecule antibiotic that has been shown to be safe
in humans. 99mTc-duramycin is rapidly cleared from
the kidneys, resulting in less off-target radiation than
99mTc-annexin-V (the most commonly used apoptosis
imaging agent). We have shown its utility in atheroma
(45), MI (46), and chemotherapy-related cardiac
damage imaging (47). These studies show that use of
duramycin, a well-tested small antibiotic molecule, is
safe in humans and might offer better clinical trans-
lation of apoptosis imaging.
Given the limitations of annexin-V imaging, other
PS-homing agents targeting the C2A domain of syn-
aptotagmin (48) have been tried in animal models
FIGURE 2 Magnetic Resonance Molecular Imaging of Cell Death
A B
A C
C D
B D
MYOCARDIAL NECROSIS WITH Gd-TO
1.8
0
R1
(S-1)
MYOCARDIAL APOPTOSIS WITH ANNEXIN-CLIO
(Top) A deoxyribonucleic acid (DNA)–binding gadolinium chelate (Gd-TO) has been used
to speciﬁcally detect the exposed DNA in acutely necrotic cells (that have lost their
sarcolemmal integrity) in vivo. The ﬁgure compares magnetic resonance (MR) images in
mice with acute myocardial infarcts injected with either gadolinium ﬂuorochrome thia-
zole orange (Gd-TO) (A and B) or gadolinium diethylenetriaminepentacetate
(Gd-DTPA) (C and D). The mice shown were imaged 18 to 24 h after infarction. Both mice
Continued in the next column
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482when labeled with either 99mTc, nanoparticles
(49,50), or probes targeting exposed histones (51).
They have not reached human use yet for evaluating
cardiac apoptosis.
MR imaging techniques for apoptosis imaging. CMR im-
aging can detect cell death through scar imaging via
LGE, and a combination of mapping techniques (T2
mapping for edema, T1 mapping for tissue pathology)
combined with LGE can separate reversible from irre-
versible injury. Gadolinium chelates, which increase T1
relaxation, and iron oxide nanoparticles, which
enhance T2 relaxation, are the most commonly used
MR imaging contrast agents for apoptotic imaging.
CMR using super paramagnetic agents works well to
image apoptosis in animal studies (42,52,53). Many
different and novel nanoparticles are being studied to
image apoptosis without radiation and with better
topographic localization (42,54). All still involve a
similar paradigm using an apoptosis-sensing ligand
(often annexin-V, or more recently, the C2A domain ofshowed severe wall motion abnormalities in their anterior, lateral,
and inferior walls, consistent with extensive infarcts. The arrow
in A points to the uninjured septum. (A and B) Robust accumu-
lation of Gd-TO is seen in the infarct 2 to 3 h after injection,
producing signal hyperintensity and high R1 values. (C) In
contrast, 2 to 3 h after the injection of Gd-DTPA, there is no sign
of an increase in signal intensity in the infarct, which is nulled
and isointense with the septum. The arrow in C points to the
pericardial fat, which marks the outer border of the infarcted
myocardium. (D) R1 map of the mouse injected with Gd-DTPA
shows no increase in R1. Thus, Gd-TO is retained in
acute myocardial infarcts, whereas GD-DTPA is not. TO not
only allows sites of injury to be identiﬁed with molecular imag-
ing, it simultaneously exerts an anti-inﬂammatory and
cytoprotective effect. Ergo, TO could be of signiﬁcant
diagnostic and therapeutic (theranostic) utility in a broad range
of conditions, including ischemia, trauma, burns, sepsis, and
autoimmune disease. Adapted from Huang et al. (17). (Bottom)
MR imaging of myocardial apoptosis in live mice after transient
coronary artery ligation. Annexin-V–cross-linked iron oxide
(AnxCLIO)-Cy5.5 (2 mg Fe/kg) or CLIO-Cy5.5 (2 mg Fe/kg)
was injected into the tail vein of the mouse directly
after LAD ligation for 30 min. MR imaging was performed on a
9.4-T scanner 24 h later. Representative frames from FLASH
cine acquisitions (TE 4.7 ms) are shown: (A) AnxCLIO-Cy5.5
diastolic frame, and (B) CLIO-Cy5.5. Well-deﬁned zones of
myocardial hypokinesis were seen in the anterior/anterolateral
walls of all mice. However, signal loss, indicative of probe
accumulation, was seen only in the hypokinetic zones of
mice that had received AnxCLIO-Cy5.5 (A), and not in those
that had received CLIO-Cy5.5 (B). In vivo corresponding T2*
maps in mice receiving Anx-CLIO-Cy5.5 (C) and CLIO-Cy5.5
(D). T2* maps were created in a region-of-interest (ROI)
in the myocardium, deﬁned by the zone of hypokinesis. A
signiﬁcant reduction in myocardial T2* values was seen in the
ROI. Modiﬁed from Sosnovik et al. (41).
FIGURE 2 Continued
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483synaptotagmin-I or a newer PS-binding hexapeptide
[TLVSSL]) linked with an imaging molecule (e.g.,
dextran or citrate-coated, cross-linked magnetic
nanoparticles with small iron oxide cores), and studies
are mainly in cancer. Apoptosis-sensing nanoparticles
have been used for in vivo imaging in the mouse heart
with acute ischemia as well as in cardiomyopathy due
to Gaq-overexpression (15,55). One of the strengths of
using apoptosis-sensing magneto-nanoparticles is the
ability to localize apoptosis, determine its extent,
and correlate it with morphology and functional
consequences (15). This avoids the anatomic and
functional uncertainty that come from just using
radiolabeled apoptosis-sensing molecules. However,
macrophages can eat up nanoparticles; thus, these
techniques might be best suited only in cardiac
diseases without signiﬁcant inﬂammation or macro-
phage inﬁltration,whichmay be a limitation compared
to 99mTc-annexin-V or duramycin imaging. Clinical
data is still far away. Proton magnetic resonance
spectroscopy and diffusion-weighted MR imaging
have been used to detect bulk apoptosis in organs,
especially during cancer therapeutics, but have not
had extensive studies in the heart.
CMR techniques are rapidly improving, and it
is now possible to identify reversible tissue injury
from that likely to become irreversible. LGE accu-
rately deﬁnes scar and irreversible infarcted
myocardium, whereas edema detected by the black-
blood T2-weighted techniques in the past and more
recently via T1 and T2 mapping techniques (where
free water prolongs both) permit deﬁning area of risk,
determining degree of damage, separating reversible
versus irreversible parts of infarcted tissue in the
subacute phase of acute MI (56–58), and predicting
recovery. However, these techniques image large
areas of myocardial damage and do not speciﬁcally
detect apoptosis or other speciﬁc cellular forms of
cell death. Thus, traditional annexin-V imaging will
still retain a role in speciﬁcally imaging apoptotic cell
death rather than just identifying dead or potentially
survivable areas in the heart.
Potential new techniques. Some newer techniques
might hold a promise of better imaging for cell death
processes. One such technique is multispectral opto-
acoustic tomographic imaging, where tissues
absorbing near-infrared (NIR) light generate ultra-
sonic waves that are converted into images of good
optical contrast and signal-to-noise ratio. These high-
resolution cross-sectional or 3-dimensional images
have limited depth at this time (a few centimeters at 5
MHz), but will surely improve in the near future.
Tagging apoptotic probes, like C2A domain of
synaptotagmin-I, with NIR ﬂuorophores producesimaging tracers that can bind PS on apoptotic cell
surfaces and can be used to image cell death within
an entire volume, say in a tumor. Measurements
made at several NIR wavelengths can also enable real-
time imaging of chromophores. Cancer applications
abound (59), but multispectral optoacoustic tomog-
raphy has been used in imaging MI (60) and for
detecting vulnerable plaque in coronaries, carotid
and peripheral arteries, when coupled with intravas-
cular catheters (61,62).
NONEXTERIORIZED TARGETS FOR IMAGING
APOPTOSIS AND CELL SURVIVAL
The cancer data contains a fair amount of emerging
publications focusing on nonexteriorized targets,
such as executioner caspases and mitochondrial
membrane potential imaging. There is nearly no
published data about this for noninvasive cardiac
imaging, and these will be brieﬂy addressed only to
describe what may be possible in future for cardiac
imaging.
MEMBRANE INTEGRITY TARGETS. Mitochondrial-
targeted myocardial tracers, which evaluate mito-
chondrial membrane integrity, voltage gradients, and
viability, are under rapid development and might
allow one to study metabolism and early apoptotic
changes, and predict viability better, especially when
used with hybrid imaging (e.g., PET-CT or PET-MR).
The outer mitochondrial membrane is an important
permeability barrier between the mitochondrion and
the cytoplasm and regulates the coupling of cellular
respiration and apoptosis. The mitochondrial inner
membrane creates transmembrane polarity (negative
inside) and is needed for proper function and to
protect against apoptosis.
Some lipid permeable compounds aggregate in cell
cytoplasm and mitochondria in a voltage-dependent
manner and can thus act as a voltage sensor,
because uptake is dependent on maintenance of
adequate mitochondrial voltage. Mitochondrial
membrane potential is reduced in apoptosis, and this
sine qua non acts as a durable ﬁngerprint of cellular
apoptosis and is associated with decreased uptake of
such compounds (63). This can be tracked with PET
tracers, but as yet there is only very preliminary data
on its ability to track cardiac apoptosis (64). 99mTc
methoxyisobutylisonitrile (MIBI) accumulates in
mitochondria with the highest negative potential,
which correlates with healthy mitochondria and
intact membrane permeability (65). A lack of
99mTc-MIBI uptake can predict cells with damaged
mitochondrial membrane potential; this imaging
technique has been used to predict cancer cells that
FIGURE 3 Images of Unstable Atherosclerotic Carotid Artery Lesions Obtained With Radiolabeled Annexin-V
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(A) Transverse and coronal views obtained by single-photon emission computed tomography (SPECT) in Patient 1, who had a left-sided
transient ischemic attack (TIA) 3 days before imaging. Although this patient had clinically signiﬁcant stenosis of both carotid arteries, uptake
of radiolabeled annexin A5 is evident only in the culprit lesion (arrows). Histopathological analysis of an endarterectomy specimen from
Patient 1 (B) (polyclonal rabbit anti–annexin A5 antibody, 400) shows substantial inﬁltration of macrophages into the neointima, with
extensive binding of annexin A5 (brown). In contrast, SPECT images of Patient 3 (C), who had a right-sided TIA 3 months before imaging, do
not show evidence of annexin A5 uptake in the carotid artery region on either side. Doppler ultrasonography revealed a clinically signiﬁcant
obstructive lesion on the affected side. Histopathological analysis of an endarterectomy specimen from Patient 3 (D) (polyclonal rabbit
anti–annexin A5 antibody, 400) shows a lesion rich in smooth-muscle cells, with negligible binding of annexin A5. Reprinted with
permission from Kietselaer et al. (33). ANT ¼ anterior; L ¼ left.
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484are unlikely to respond to chemotherapy, but has not
been investigated in cardiac cell death.
There are other agents under development that
might overcome the limitations of MIBI-like com-
pounds. Lipophilic cations, like the positively
charged 18F-labeled triphenyl phosphonium probes
can be used to assess apoptosis-related mitochondrial
dysfunction by detecting the loss of mitochondrial
membrane potential (DJm) (63). Further improve-
ments in triphenyl phosphonium chemistry will pro-
vide clinically usable mitochondrial voltage as well as
viability probes (66). Rhodamine dyes have also beenused as 18F-labeled probes directly evaluating the
integrity loss of mitochondrial membrane potential,
because they also accumulate in the mitochondria in
proportion to membrane potential (67). Robust clin-
ical studies are as yet awaited.
EXECUTIONER CASPASE TARGETS. Many of the
steps that can be imaged in the apoptotic process
(Central Illustration), although showing promise in
cancer imaging and elsewhere, have not reached
maturity for noninvasive imaging of cardiac
apoptosis. Imaging the intracellular cell death
executioner machinery like caspases 3 or 7 sounds
FIGURE 4 Clinical Imaging of Myocardial Infarction
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Myocardial apoptosis has clinically been evaluated by indium-111–labeled annexin-V, an endogenous protein that targets abundant surface
exposure of phosphatidylserine (PS), normally a resident of the inner lamella of sarcolemma. Exteriorized PS mediates phagocytosis of
apoptotic cells by macrophages. Annexin-V avidly binds to PS with nanomolar afﬁnity. Annexin uptake is distinctly seen in the anteroseptal
(top, left) and antero-apical (bottom, left) regions. Annexin-V uptake clearly conforms to sestamibi-detected zones of myocardial perfusion
deﬁcit (right, top and bottom). The transverse tomographic images were obtained 18 h after MI, and MIBI images after 6 weeks. High liver
uptake might occasionally interfere with annexin uptake in inferior myocardial regions, a problem that is being addressed with PE-seeking
duramycin targeting of apoptosis. Adapted from Hofstra et al. (2). L ¼ liver.
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485attractive, but is beset with a number of issues
including the need to have either cell permeable
probes (68) or a cell with increased membrane
permeability. Caspase imaging may not be speciﬁc,
and caspase activation is dynamic, which makes it
difﬁcult to quantitatively time and target a particular
marker caspase. 11C or 18F-labeled small molecule
caspase inhibitor isatins can be imaged with PET to
detect caspase activity, as shown in hepatic cells (69).
Other probes need to be activated by such intracel-
lular targets and the reporter molecules (70), but may
be limited due to difﬁculties in uptake or internali-
zation, or nonspeciﬁc cleavage by other proteases
(71). Caspases may not be deﬁnitively associated withcell death, which makes imaging cell death a bit
challenging (72,73). Finally, such imaging probes are
often expelled through P-glycoprotein trans-
membrane efﬂux pumps (74), which makes imaging
caspases cumbersome. Many probes are based on
optical imaging (71), but nuclear imaging-based
probes are soon to come (69). Although some have
been tested in humans (75), they are still far from
meaningful use. No signiﬁcant body of cardiac imag-
ing exists for any of these strategies, but recent study
showed that a caspase-3-PET tracer, 18FWC-4-116,
imaged caspase activity during myocardial apoptosis
in a rat IR model, suggesting the potential to monitor
caspase activity during myocardial injury (76).
FIGURE 5 Myocardial Apoptosis in Heart Failure
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Myocardial apoptosis plays an important role in heart failure progression and is amenable to molecular imaging. (A) Molecular basis of
apoptosis imaging in heart failure. Unlike acute myocardial insults, such as in myocardial ischemia and inﬂammation, the slow inexorable
process of apoptosis that is mediated by proapoptotic intracellular signaling (pink) allows concurrent up-regulation of antiapoptotic (green)
factors. Even after abundant release of cytochrome c1 release from mitochondria into the cytoplasmic compartment, apoptosis is largely
prevented by the simultaneous presence of the IAPs and Bcl2 family of proteins. Uninhibited activation of caspase-8 and residual activated
caspase-9 lead to low-level caspase-3 activation. There is contractile proteolysis and vacuole formation. DNA fragmentation is usually
prevented. The residual activated caspase-3 induces cell membrane changes and helps exposure of phospholipids such as PS and PE. The
greater the intracellularly activated caspase-3 (pro-apoptotic mediators stronger than antiapoptotic factors), the more likelihood of a
positive annexin-V scan, and the less likelihood of favorable clinical outcome. Adapted from Kietselaer BL, Reutelingsperger CP, Boersma
HH, et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin V5 in heart failure. J Nucl Med 2007;48:562–7.
Continued on the next page
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486TRANSLATIONAL OPPORTUNITIES IN
IMAGING FOR APOPTOSIS
CLINICAL AND EXPERIMENTAL DATA. Unlike can-
cer, where cell death is a desirable endpoint, cell
death, especially of the apoptotic form, is a common
but undesirable occurrence in cardiac diseases, given
its limited potential for regeneration. Many cardiac
diseases have ongoing low-level apoptosis that is
thought to underlie myocyte loss and chronic
dysfunction. This hypothesis remains controversial
(77) and is not entirely proven in human studies, but
it seems quite convincing in animal experiments,
where apoptotic machinery was manipulated to
induce a pro-apoptotic milieu.ATHEROSCLEROSIS. Atherosclerotic plaque rupture
is associated with the majority of the acute coronary
events (Figure 3). The high-risk plaque precursors of
plaque rupture are usually extensively positively
remodeled to carry large lipid cores that are sepa-
rated from lumen by a very thin ﬁbrous cap. Ongoing
apoptosis of the plaque microconstituents, such as
macrophages and smooth muscle cells, contributes
to core enlargement and cap thinning and perpetu-
ates plaque instability (78,79). Plaque stability is,
among other things, inﬂuenced by the ability of
macrophages in plaque to ingest and clear apoptotic
bodies (i.e., “efferocytosis”); defective efferocytosis
facilitates formation of a necrotic core, because
uncleared apoptotic bodies swell and shed their
FIGURE 5 Continued
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(B) Cytochrome c1 distribution and nuclear morphology in control and cardiomyopathic hearts. Light microscopy immunohistochemistry with
anticytochrome c antibody in myocardial specimens (100) revealed signiﬁcant differences in distribution of cytochrome c1 and nuclear
morphology. (B1) Transverse section of control heart. The mitochondria-speciﬁc immunostain assumes a typical zebra-like distribution pattern
(arrows). (B2) In longitudinal sections of a control heart, the easily recognizable sarcomeres are not stained (arrows). (B3) Immunoelectron
microscopy of a normal heart documents mitochondria decorated by the gold-conjugated anticytochrome c antibody particles (56,000).
(B4) Light microscopy of the dilated cardiomyopathy sample shows that the anticytochrome c antibody has stained both mitochondrial and
nonmitochondrial structures, including sarcomeres (100). The same section contains both longitudinally (black arrows) and transversally (blue
arrow) cut myocytes. Nuclei are morphologically nonapoptotic. (B5) The immunoelectron microscopy shows that anticytochrome c1 antibody
decorate both mitochondria and nonmitochondrial structures, including sarcomeres (26,000). B1, B2, and B4 show staining with avidin-
biotin complex; B3 and B5 show staining with uranyl acetate and lead citrate. Adapted from Haider N, Arbustini E, Gupta S, et al. Concurrent
upregulation of endogenous proapoptotic and antiapoptotic factors in failing human hearts. Nat Clin Pract Cardiovasc Med 2009;6:250–61.
Continued on the next page
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487contents to damage surrounding tissues. Therefore,
expansion of necrotic core is likely the consequence
of accelerated macrophage apoptosis and ineffective
efferocytosis (80,81). It has been suggested that
apoptosis may help promote thrombosis on ruptured
plaques (82).
Atherosclerosis in the carotid artery, abdominal
aorta, and coronary arteries has been investigated for
apoptosis with noninvasive methods. SPECT-CT
imaging with either 99mTc-labeled annexin-V or,
more recently, 99mTc-radiolabeled duramycin from
our laboratory (45) has been used most often fortargeting apoptosis and correlates well with histo-
logical ﬁndings (83) of apoptosis in macrophages (84)
or smooth muscle cells (85) in the carotid arteries,
abdominal aorta, as well as the coronary arteries.
Apoptosis imaging has also been used to non-
invasively determine the effects of plaque-
passivating therapies (86). Human studies are
fewer, but may be promising to differentiate stable
from unstable plaques as in patients with stroke or
transient ischemic attack (33). Such studies offer
hope of being able to noninvasively monitor high-risk
plaques and the effect of therapy.
FIGURE 5 Continued
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(C) Incremental value of circulating annexin-V over conventional biomarkers for predicting mortality in heart failure. Circulating annexin-V
levels are increased in heart failure and can be measured for prognostication. The data are developed from 180 heart failure patients and 20
control subjects, wherein 20 heart failure deaths occurred during follow-up. Kaplan-Meier plots (C1 to C4) are shown based on the optimal
cut-off values derived from receiver-operating characteristic curve analysis (C5) for N-terminal pro–B-type natriuretic peptide (NT-proBNP)
(C1), annexin-V þ NT-proBNP (C2), NT-proBNP þ estimated glomerular ﬁltration rate (eGFR) þ C-reactive protein CRP (C3), and
annexin-V þ NT-proBNP þ eGFR þ CRP (C4) to predict mortality in patients with heart failure. CR ¼ combined risk. (C5) Receiver-operating
characteristic curve analysis to predict 3-year mortality in patients with heart failure is presented for N-terminal pro–B-type natriuretic peptide,
eGFR, and CRP (solid line), annexin-V alone (dashed line), and annexin-V combined with NT-proBNP, eGFR, and CRP (dotted line). (C6) A
myocardial sample obtained from a nonischemic cardiomyopathy patient was investigated for in situ annexin-V localization by direct im-
munostaining with antiannexin-V antibody. Substantial localization of annexin-V is seen in the interstitium and intracellularly. This suggests
that annexin-V is increasingly produced in myocardium (as also other organs, data not shown) and hides cell surface apoptotic signals to
protect myocytes from phagocytosis. The annexin-V levels are expected to represent long-term status of myocardial pathology, unlike acute
markers such as NT-proBNP. Modiﬁed from Schurgers LJ, Burgmaier M, Ueland T, et al. Circulating annexin A5 predicts mortality in patients
with heart failure. J Intern Med 2016;279:89–97.
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FIGURE 6 Apoptosis Imaging in Transplant Rejection
TUNEL
SA VLA HLA
Annexin-V imaging 9 months after orthotopic heart transplantation. (Top) Single-photon emission computed tomography (SPECT) imaging
3 h after intravenous injection of radiolabeled annexin-V demonstrated multifocal myocardial uptake of radiotracer. Smoothening of the
images and cardiac SPECT processing in the short axis (SA), vertical long axis (VLA), and horizontal long axis (HLA) revealed myocardial
perfusion scan-like images with diffuse uptake in whole myocardium, suggesting apoptosis in the myocardium. (Bottom) Right ventricular
EMB was performed within 24 h of the scan that revealed ISHLT grade 2R (previously 3A/4) rejection characterized by lymphomononuclear
cell inﬁltration and at least 2 foci of myocyte necrosis; 1 focus of myocyte necrosis associated with intense inﬂammation is shown (H&E
staining; magniﬁcation, 40, left). Positive TUNEL staining (brown) was observed in occasional myocytes, lymphomononuclear cells, and
endothelial cells (right).
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489MYOCARDIAL ISCHEMIA AND MI. Apoptosis has re-
ported in myocardial ischemia, and more prominently
in the border zone of MI with reperfusion injury (87)
(Figure 4). Coronary artery occlusion with or without
reperfusion was one of the initial models of edema
cell death (88); both apoptosis and necrosis occur
mainly in the infarct zone, and to a lesser degree in
the peri-infarct zone as well as in the remodeled
remote myocardium in a time and stimulus
magnitude-dependent manner (89). Apoptosis starts
within minutes of ischemia and precedes necrosis by
many hours after MI. Apoptosis persists long after the
necrotic event, and slow ongoing apoptotic cell loss
over years is thought to be responsible for ventricular
remodeling and progression of heart failure (90,91).
Modulating apoptosis reduces infarct size (91) and
might be a way to attenuate left ventricular
dysfunction in post-infarct patients (92). There are
animal data that attenuating apoptosis in a number
of ways can attenuate infarct size, ventricular
remodeling, and eventual heart failure. Apoptosis is
detectable in human MI (2) (Figure 4), but as yet thereis no human data convincingly showing the beneﬁt of
antiapoptotic intervention in human acute MI. Nec-
roptosis is now being recognized in ischemia-
reperfusion injury in the heart, kidney, and brain,
and early studies show that inhibiting it seems to be
beneﬁcial (7).
Apoptosis imaging in acute MI or ischemia-
reperfusion injury has mainly employed 99mTc-
annexin-V with SPECT to target PS, CMR probes to
target DNA fragments, and less commonly, some
other strategies (15,16,33,93,94). Translation into hu-
man studies has been slow due to a number of issues,
and introduction of small molecule agents like dura-
mycin might change the ﬁeld. Preliminary studies
using 99mTc-labeled annexin-V SPECT imaging
demonstrate the ability to show and possibly size
infarcted areas in patients with MI undergoing pri-
mary PCI (2,95). 99mTc-annexin-V uptake matched the
MI location; the time course suggested early
apoptosis that declined with time, and SPECT defect 6
weeks later matched areas of 99mTc-annexin-V up-
take. Future improvements in noninvasive apoptosis
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490imaging might allow for rapid triage of patients with
the highest risk for cell death as well as map the
beneﬁt of therapeutic intervention.
APOPTOSIS IN HEART FAILURE AND
CARDIAC TRANSPLANTATION
Apoptosis in human heart failure was ﬁrst described
by Narula et al. (96) and was quickly conﬁrmed by
other groups (97) (Figures 5 and 6). Chronic ongoing
apoptosis may have a role in remodeling and in the
subsequent development of heart failure both in
post-infarct ischemic or nonischemic cardiomyopathy
(96–98). However, its prevalence is low (<0.1% ter-
minal deoxynucleotidyl transferase dUTP nick-end
labeling-positive cells) (97), and smoldering low-
level apoptotic activity in failing human hearts (97)
is thought to contribute to cumulative myocyte loss
and eventual progression of heart failure (98). Miti-
gation of apoptosis during genetic manipulation or
pharmacological apoptotic inhibition (99,100) can be
effectively imaged noninvasively, but animal models
have higher levels of apoptosis than shown in chronic
human heart failure. This might pose difﬁculties in
translating animal data into humans, which will be
necessary if apoptosis imaging is to have funda-
mental clinical utility. Because chronic ongoing
apoptosis is a tussle between concurrent up-
regulation of intracellular pre- and anti-apoptotic
mediators, cardiomyocytes demonstrate a strong
survival instinct (6) that renders myocytes into a hi-
bernating mode. These cells exist as inactive or
zombie cells (6) and may recover upon elimination of
etiologic agent or providing antiapoptotic support
(99–101). Tracking apoptotic death and predicting cell
survival in chronic heart failure will be an exciting
frontier in heart failure imaging.
Apoptosis has been demonstrated in myocarditis
(102) in some but not all studies (103) and correlates
with heart failure death but not sudden cardiac death,
suggesting its role in fatal heart failure. Human
studies of enterovirus-related myocarditis biopsy
specimens conﬁrm apoptosis that correlated with
viral load and clinical severity (104). Antiapoptotic
agents decrease the severity of myocarditis in animal
models, but the relation in human disease, including
human immunodeﬁciency virus cardiomyopathy, is
unclear. Imaging has shown the presence of
histology-proven apoptosis in myocarditis (105,106)
and doxorubicin-induced cardiac damage (107).
Apoptosis (programmed cell death) is a feature of
clinical and experimental immunological myocarditis
in the form of transplant rejection (108). 99mTc-
annexin-V shows uptake colocalizing to apoptosis inrodent myocarditis (105,109). Human data is lacking,
but strikingly positive animal data offers the promise
that such imaging might detect early damage, stratify
patients for advanced therapies, and allow serial
monitoring of damage and improvement. Early data
show such promise in cardiac transplant rejection,
which has some similarities with inﬂammatory car-
diac dysfunction. Human studies in a small number of
subjects post-cardiac transplant showed the utility of
apoptosis imaging with 99mTc annexin-V SPECT.
Although promising, this technique still lacks
adequate speciﬁcity (3,110). New tracers might
improve this delay to translation.
CONCLUSIONS
Cell death is an attractive target for noninvasive im-
aging with an aim to understand pathophysiology,
diagnose and predict myocyte loss, track disease ac-
tivity to potentially modulate course, and evaluate
response to therapeutic intervention. Apoptosis
seems to be the most promising target for imaging cell
death that can be reversible under certain conditions
and may be modulated with present and future in-
terventions. Although necrosis and to a certain
extent, autophagy can also be imaged, the utility of
such imaging is less clear. Multiple strategies, often
involving an apoptosis-sensing ligand paired with an
imageable reporter molecule (nuclear, optical, or
CMR-based), have been designed to target multiple
intermediate steps in the apoptosis cascade. Animal
studies are more promising, showing deﬁnitive proof
for existence of signiﬁcant apoptosis in many
different cardiac diseases, contribution of apoptosis
to progression of disease, and beneﬁt of antiapoptotic
modulation. Human studies evaluating cardiac
apoptosis have involved only very few patients, are
more than a decade old, and remain inconclusive,
but they show feasibility of monitoring apoptosis.
However, there is a lot of innovative activity in this
ﬁeld, including the development of new imaging
probes that might be conducive to multimodal
hybrid imaging systems and greater use of nano-
particles that promise theranostic paradigms (111).
These technologies offer signiﬁcant promise, espe-
cially in tracking apoptosis in cancer patients, and
many are in phase 2/3 trials; they are likely to move
the ﬁeld forward with eventual migration to cardiac
diseases.
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